Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Sells $278,100.00 in Stock

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Mark J. Gergen sold 30,000 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the completion of the transaction, the chairman now directly owns 651,291 shares of the company’s stock, valued at approximately $6,037,467.57. This represents a 4.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Poseida Therapeutics Price Performance

Shares of Poseida Therapeutics stock opened at $9.31 on Friday. The firm has a market cap of $907.35 million, a PE ratio of -14.78 and a beta of 0.54. Poseida Therapeutics, Inc. has a twelve month low of $1.87 and a twelve month high of $9.42. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The business has a 50-day moving average price of $3.25 and a 200 day moving average price of $3.10.

Institutional Trading of Poseida Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Poseida Therapeutics by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after acquiring an additional 473,746 shares during the period. State Street Corp grew its position in shares of Poseida Therapeutics by 2.3% in the third quarter. State Street Corp now owns 1,710,565 shares of the company’s stock valued at $4,892,000 after purchasing an additional 38,770 shares during the period. Blair William & Co. IL increased its stake in shares of Poseida Therapeutics by 14.1% during the second quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock worth $3,216,000 after purchasing an additional 136,273 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after purchasing an additional 297,500 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Poseida Therapeutics by 89.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock valued at $2,648,000 after buying an additional 391,801 shares in the last quarter. 46.87% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday. BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday. Cantor Fitzgerald cut shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $9.00 price objective (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, Poseida Therapeutics currently has an average rating of “Hold” and an average price target of $9.50.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.